Merck KGaA
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Merck KGaA, headquartered in Darmstadt, Germany, and founded in 1668, operates as a leading science and technology company with three core business sectors: Healthcare; Life Science; and Electronics; serving customers in over 65 countries across Europe, North America, Asia-Pacific, Latin America, the Middle East, and Africa. In Healthcare, the company discovers, develops, manufactures, and markets prescription pharmaceuticals and biopharmaceuticals focused on oncology (including Erbitux and Bavencio), neurology and immunology (such as Rebif and Mavenclad for multiple sclerosis), fertility (featuring Gonal-f), and cardiology, metabolism, and endocrinology; in Life Science, it provides science and lab solutions (reagents, consumables, instruments, and services under brands like Sigma-Aldrich, MilliporeSigma, Milli-Q, and Bioreliance), process solutions (filtration, chromatography, single-use systems for biopharma manufacturing), and life science services (including CDMO and contract testing for biotech, pharma, diagnostics, academia, and industrial clients); in Electronics, it supplies semiconductor solutions, display solutions (liquid crystals), and surface solutions (effect pigments, cosmetics, and functional materials for automotive, consumer electronics, and industrial applications). Recent major developments include the completion of its $3.4 billion acquisition of SpringWorks Therapeutics in July 2025 to bolster its oncology pipeline with rare tumor therapies like Ogsiveo (niacestant) and mirdametinib; a September 2025 memorandum of understanding with Siemens to extend their partnership for AI-driven drug discovery, development, and manufacturing using Dotmatics technology; a €70 million investment announced in October 2024 to expand antibody-drug conjugate (ADC) manufacturing capacity in St. Louis, Missouri; and a $1.4 billion multi-year collaboration with Caris Life Sciences in April 2025 for tumor target identification to advance its internal ADC candidate M9140.
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript
Merck KGaA Q1 Earnings Call Highlights
Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Merck KGaA: Small Breakout In 2026, Followed By Normalization
Head-To-Head Analysis: Merck KGaA (OTCMKTS:MKGAF) vs. Athersys (NASDAQ:ATHX)
TrumpRx lists many medicines at prices higher than paid in UK
Merck KGaA (OTCMKTS:MKGAF) & Calithera Biosciences (NASDAQ:CALA) Head to Head Contrast
Merck KGaA (MKKGY) Q4 2025 Earnings Call Transcript
Merck KGaA (MKKGY) Q4 2025 Press Conference Call Transcript
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO
Financial Comparison: Virpax Pharmaceuticals (NASDAQ:VRPX) versus Merck KGaA (OTCMKTS:MKGAF)
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Financial Comparison: Merck KGaA (OTCMKTS:MKGAF) versus AEON Biopharma (NASDAQ:AEON)
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
Merck KGaA (MKKGY) Q3 2025 Earnings Call Transcript
MusclePharm (OTCMKTS:MSLP) and Merck KGaA (OTCMKTS:MKGAF) Head-To-Head Analysis
Merck KGaA: An AI-Resistant Pharma Play
Trump rolls out his latest deal with a drugmaker. This one stems from his campaign promise to cover all IVF costs.